Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its ...

Valneva said it has been supplying Ixchiq to help the French government respond to a major outbreak of chikungunya in La ...

A preliminary discussion on an action plan to eradicate the rapidly spreading dengue cases and Chikungunya virus infections, ...

the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ ® for the prevention of disease caused by the chikungunya virus ...

They are among the first in Sweden to be vaccinated against the chikungunya virus - a vaccine that is the result of a ...

Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash.

The Aedes mosquitos also carry the Chikungunya virus (CHIKV), which causes Chikungunya. According to the Journal of Vector Borne Disease, chikungunya, and dengue share not only endemic regions but ...

the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ for the prevention of disease caused by the chikungunya virus (CHIKV ...

Shares in Valneva plunged after the company said France's health authorities suspended the use of its chikungunya vaccine, Ixchiq, for people aged 65 and older, raising concerns about the vaccine's ...